BIIB
BIOGEN INC.
+1.79 (+0.83%)217.80USD203K成交股數32.2B市值23.4本益比(近四季)3.2股價營收比+1.9%營收年增(近四季)2026-10-28下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 | 22Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 2.5B+1% | 2.5B+3% | 2.6B+7% | 2.4B+6% | 2.5B-3% | 2.5B+0% | 2.5B+0% | 2.3B-10% | 2.5B | 2.5B | 2.5B | 2.5B |
| 營業成本 | 661M | 674M | 605M | 629M | 584M | 639M | 546M | 542M | 660M | 593M | 663M | 571M |
| 毛利 | 1.8B-3% | 1.9B+2% | 2.0B+6% | 1.8B+3% | 1.9B+0% | 1.8B-2% | 1.9B+7% | 1.7B-11% | 1.9B | 1.9B | 1.8B | 2.0B |
| 毛利率 | 73.3% | 73.4% | 77.1% | 74.1% | 76.2% | 74.1% | 77.8% | 76.3% | 73.9% | 75.9% | 73.1% | 77.6% |
| 研發費用 | 539M | 436M | 399M | 434M | 513M | 516M | 505M | 445M | 736M | 584M | 571M | 602M |
| 銷售管理費用 | 607M | 595M | 584M | 573M | 680M | 588M | 554M | 582M | 788M | 548M | 605M | 633M |
| 營業利益 | – | – | – | – | – | – | – | – | – | – | – | – |
| 營業利益率 | – | – | – | – | – | – | – | – | – | – | – | – |
| 稅後淨利 | 320M+20% | 467M+20% | 635M+9% | 241M-39% | 267M-491% | 389M-34% | 584M+50% | 393M-29% | −68.1M | 592M | 388M | 551M |
| 淨利率 | 12.9% | 18.4% | 24.0% | 9.9% | 10.9% | 15.8% | 23.7% | 17.2% | -2.7% | 24.1% | 15.7% | 21.6% |
| 稀釋 EPS | 2.15+18% | 3.17+19% | 4.33+8% | 1.64-39% | 1.82-487% | 2.66-35% | 4.00+50% | 2.70-28% | -0.47 | 4.07 | 2.67 | 3.73 |
| 稀釋股數 | 148M | 147M | 147M | 147M | 146M | 146M | 146M | 146M | 145M | 146M | 145M | 146M |
資產負債表 期末餘額
| 科目 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 | 22Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 3.4B | 3.9B | 2.8B | 2.6B | 2.4B | 1.7B | 1.9B | 1.1B | 2.3B | 2.6B | 2.9B | 3.4B |
| 應收帳款 | – | – | – | – | 1.4B | – | – | – | – | – | 1.6B | 1.7B |
| 存貨 | 1.9B | 2.2B | 2.3B | 2.3B | 2.5B | 2.5B | 2.5B | 2.5B | 3.0B | 1.3B | 1.3B | 1.3B |
| 總資產 | 29.5B | 29.2B | 28.3B | 28.0B | 28.0B | 28.3B | 26.8B | 26.6B | 28.2B | 25.2B | 24.6B | 24.6B |
| 有息負債 | 6.3B | 6.3B | 6.3B | 4.5B | 4.5B | 4.5B | 6.3B | 6.3B | 6.8B | 6.3B | 6.3B | 6.3B |
| 總負債 | 10.8B | 11.0B | 10.7B | 11.1B | 11.3B | 12.0B | 10.9B | 11.4B | 13.7B | 10.7B | 10.8B | 11.2B |
| 股東權益 | 18.7B | 18.2B | 17.6B | 17.0B | 16.7B | 16.4B | 15.9B | 15.2B | 14.5B | 14.5B | 13.8B | 13.4B |
| 負債比 | 36.7% | 37.7% | 37.8% | 39.4% | 40.4% | 42.2% | 40.7% | 42.7% | 48.6% | 42.5% | 44.0% | 45.5% |
| 淨現金(現金 − 有息負債) | −2.9B | −2.4B | −3.5B | −2.0B | −2.2B | −2.8B | −4.4B | −5.2B | −4.5B | −3.7B | −3.4B | −2.9B |
現金流量表 單季
| 科目 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 | 22Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | 646M | – | – | 259M-53% | – | – | – | 553M | – | – | 455M | – |
| 資本支出 | 51.2M | – | – | 37.1M | – | – | – | 45.9M | – | – | 66.6M | – |
| 自由現金流 | 594M | – | – | 222M-56% | – | – | – | 507M | – | – | 389M | – |
| 折舊攤銷 | 204M | – | – | 183M | – | – | – | 148M | – | – | 112M | – |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | 24.0% | – | – | 9.1% | – | – | – | 22.1% | – | – | 15.8% | – |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
業務分部2025 年度 · 9.9B
| Reportable | 9.9B | 100.0% | +2.2% |
|---|
產品／服務2025 年度 · 1.00
| 產品 小計 | 7.1B | 711940000000.0% | -1.3% |
|---|---|---|---|
| MS Product Revenues 小計 | 4.0B | 403890000000.0% | -7.1% |
| Rare Disease Product Revenue 小計 | 2.2B | 215420000000.0% | +8.4% |
| Revenues From Anti CD20Therapeutic Programs 小計 | 1.9B | 186060000000.0% | +6.3% |
| Tysabri Product 小計 | 1.7B | 166540000000.0% | -2.9% |
| SPINRAZA 小計 | 1.5B | 154680000000.0% | -1.7% |
| Fumarate 小計 | 1.4B | 142650000000.0% | -10.6% |
| Royalty Attributed To OCREVUS 小計 | 1.4B | 141490000000.0% | +5.6% |
| Interferon 小計 | 946M | 94560000000.0% | -2.3% |
| VUMERITY 小計 | 747M | 74680000000.0% | +18.9% |
| Contract Manufacturing Royalty And Other Revenue 小計 | 733M | 73290000000.0% | +12.3% |
| Biosimilars 小計 | 729M | 72910000000.0% | -8.1% |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 9.9B | +2.2% | 1.3B | 13.1% | 8.79 | 2.1B |
| FY2024 | 9.7B | -1.6% | 1.6B | 16.9% | 11.18 | 2.7B |
| FY2023 | 9.8B | -3.3% | 1.2B | 11.8% | 7.97 | 1.3B |
| FY2022 | 10.2B | -7.4% | 3.0B | 30.0% | 20.87 | 1.1B |
| FY2021 | 11.0B | -18.3% | 1.6B | 14.2% | 10.40 | 3.4B |
| FY2020 | 13.4B | -6.5% | 4.0B | 29.8% | 24.80 | 3.8B |
| FY2019 | 14.4B | +6.9% | 5.9B | 41.0% | 31.42 | 6.6B |
| FY2018 | 13.5B | – | 4.4B | 32.9% | 21.58 | 5.4B |